Grit Biotechnology is a Chinese cell therapy company developing novel tumor-infiltrating lymphocyte (TIL) therapies to transform the lives of people with cancer
Grit Biotechnology is a Chinese cell therapy company developing novel tumor-infiltrating lymphocyte (TIL) therapies to transform the lives of people with cancer. Their lead product, GT101, is the first TIL product to receive Investigational New Drug (IND) approval in China and is currently in Phase 1 clinical trials.